3//SEC Filing
HealthCap VII, L.P. 3
Accession 0000899243-20-017702
CIK 0001805890other
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 8:00 PM ET
Size
11.4 KB
Accession
0000899243-20-017702
Insider Transaction Report
Form 3
HealthCap VII, L.P.
10% Owner
Holdings
- (indirect: See footnote)
Class A Preferred Exchangeable Shares
→ Common Shares (2,497,345 underlying) - (indirect: See footnote)
Warrants to purchase Class B Preferred Exchangeable Shares
Exercise: $8.10From: 2020-01-10Exp: 2022-01-10→ Common Shares (107,929 underlying) - (indirect: See footnote)
Class B Preferred Exchangeable Shares
→ Common Shares (1,069,902 underlying)
HealthCap VII GP S.A.
10% Owner
Holdings
- (indirect: See footnote)
Class B Preferred Exchangeable Shares
→ Common Shares (1,069,902 underlying) - (indirect: See footnote)
Class A Preferred Exchangeable Shares
→ Common Shares (2,497,345 underlying) - (indirect: See footnote)
Warrants to purchase Class B Preferred Exchangeable Shares
Exercise: $8.10From: 2020-01-10Exp: 2022-01-10→ Common Shares (107,929 underlying)
Footnotes (4)
- [F1]Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares of the Issuer shown in Column 3. The Class A Preferred Exchangeable Shares have no expiration date.
- [F2]The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F3]Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares of the Issuer shown in Column 3. The Class B Preferred Exchangeable Shares have no expiration date.
- [F4]Represents Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001645161
Filing Metadata
- Form type
- 3
- Filed
- Jun 24, 8:00 PM ET
- Accepted
- Jun 25, 8:00 PM ET
- Size
- 11.4 KB